The optimal antithrombotic therapy for patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention with stent (PCI-S) is still undetermined [1,2]. Current recommendations, however generally based on a level of evidence C (i.e. derived from experts' opinion and/or non-randomized, small-size data), suggest triple therapy (TT) with either a vitamin K-antagonist (VKA) or non-vitamin K antagonist oral anticoagulant (NOAC) plus aspirin and clopidogrel as the preferred strategy to prevent both thromboembolic and ischemic cardiac events [3,4].
